Biotechnology
Cancer Prevention
Health

Clovis Oncology

$24.84
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.29 (-4.94%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CLVS and other stocks, options, ETFs, and crypto commission-free!

About

Clovis Oncology, Inc. Common Stock, also called Clovis Oncology, is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Read More Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Employees
468
Headquarters
Boulder, Colorado
Founded
2009
Market Cap
1.38B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.83M
High Today
$26.33
Low Today
$24.80
Open Price
$26.05
Volume
593.66K
52 Week High
$65.24
52 Week Low
$11.50

Collections

Biotechnology
Cancer Prevention
Health
Technology

News

BusinessWireMar 19

Clovis Oncology Announces Presentations at 2019 AACR Annual Meeting

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that six abstracts highlighting progress in the Rubraca clinical development and lucitanib preclinical research programs will be presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting taking place March 29 – April 3 in Atlanta. The accepted abstracts summarize multiple clinical trials and nonclinical research in which Rubraca is being studied as single agent and combination therapy in a varie...

25
Markets InsiderMar 16

Clovis Oncology to Highlight Rubraca® (rucaparib) Data from Post-Hoc ARIEL3 Analyses at SGO 2019 Congress

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that data from post hoc exploratory analyses from the ARIEL3 Phase 3 clinical study of Rubraca will be presented during oral plenary and poster sessions at the Society of Gynecologic Oncology 2019 Congress (SGO), March 16 -19, 2019 in Honolulu, Hawaii. Data to be presented will highlight ARIEL3 results in different patient demographics, including age and deleterious germline mutation status. "The results from these post hoc analyses of the ARIEL3 study d...

134
Seeking AlphaMar 8

Clovis Oncology holder Armistice trims stake to 3.8%

Clovis Oncology (NASDAQ:CLVS) shareholder Armistice Capital has filed an amended ownership statement saying it's holding a 3.8% stake in the company.

150

Earnings

-$2.13
-$1.82
-$1.52
-$1.21
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.